Purpose: We aimed to assess the safety and efficacy of metformin for treating patients with metastatic pancreatic cancer and to identify endocrine and metabolic phenotypic features or tumor molecular markers associated with sensitivity to metformin antineoplastic action.
Introduction
The biguanide metformin is commonly prescribed for the treatment of type 2 diabetes because it lowers both glucose and insulin levels (1). Metformin was shown to have antineoplastic or chemopreventative activity in vitro (2, 3) and in vivo (4-6) models of pancreatic cancer. Metformin has two properties of potential oncologic relevance: it reduces systemic insulin and insulin-like growth factor (IGFI) levels (7) and has direct growth-inhibitory action on cancer cells (8) . In fact, metformin inhibits oxidative phosphorylation in the liver with inhibition of gluconeogenesis and hepatic glucose output (9) , which in turn reduce circulating glucose level decreasing insulin and IGFI levels (10) . This is a potential antineoplastic action because a subset of cancers displays insulin/IGFI receptors and is insulin/IGFI responsive (7) . Moreover, metformin, by accumulating in neoplastic tissue, may directly affect cancer cells primarily by decreasing insulin/IGF signaling (8, 11) , disrupting mitochondrial respiration (12) , and inhibiting the mTOR pathway by AMP-activated protein kinase (AMPK)-dependent (8, 13, 14) and -independent mechanisms (15) (16) (17) (18) . In addition, other potential direct antitumorigenic effects of metformin include the ability to downregulate specific transcription factors and associated genes (15, 19, 20) , alter microRNAs (5, 21) , decrease cancer stem cell proliferation (22, 23) , and reduce DNA damage and inflammation (24) . Pharmacoepidemiologic studies have suggested that metformin use is associated with reduced pancreatic cancer risk (25) (26) (27) (28) (29) and an improved cancer prognosis or survival (30, 31) . However, the methods of some of these studies have been criticized (32) , and results from other studies have concluded that no association exists between metformin use and pancreatic cancer risk (33) (34) (35) (36) (37) or prognosis (38) (39) (40) . There is therefore interest in testing the hypothesis that this drug might be repurposed for indications in pancreatic cancer in prospective interventional randomized trials. Here we provide the results of a monocentric open-label, randomized, phase II trial to test the efficacy of adding metformin to systemic chemotherapy in patients with metastatic pancreatic cancer.
Materials and Methods
This trial was designed as a single-centre, prospective, open-label, randomized, phase II study in which patients with pathology-confirmed diagnosis of metastatic pancreatic adenocarcinoma, were randomized to receive metformin (2 g/die; arm A) or not (arm B) in association with our standard four-drug chemotherapy regimen including cisplatin, epirubicin, capecitabine, gemcitabine (PEXG) (41) . The primary outcome measure was the progression-free survival at 6 months from treatment start (PFS-6). Secondary endpoint included overall survival (OS), progression-free survival (PFS), response rate (RR: complete response þ partial response), and safety profile. OS was defined as the time between the date of treatment start and the date of death from any cause; patients without an event (death) were censored on the date they were last known to be alive. PFS was defined as the time between the date of treatment start and the date of radiologically documented disease progression or death from any cause, whichever occurred first; patients without an event (disease progression or death) were censored on the last contact date. Response rate and the event of disease progression were defined according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1. The efficacy population was defined as all patients satisfying eligibility criteria and who received at least one dose of study treatment; the safety population was defined as all patients who received at least one dose of the study treatment. All patients provided written informed consent. The trial was approved by the San Raffaele Hospital ethics committee and was conducted following the principles of good clinical trial practice and according to the Declaration of Helsinki.
Eligibility
Patients with pathology-confirmed metastatic pancreatic adenocarcinoma, age !18 and 75 years, Karnofsky performance status !50 or >70 in patients >70 years of age, measurable disease, adequate bone marrow (leukocyte count !3,500/mm 3 , granulocytes !1,500/mm 3 , platelets !100,000/mm 3 , hemoglobin !10 g/dL), renal (serum creatinine 1.5 mg/dL or creatinine clearance !30 mL/min), and liver function (total bilirubin 2 mg/dL, alanine aminotransferase/aspartate aminotransferase 3 Â upper limit of normal and alkaline phosphatase 2.5 Â upper limit normal, creatine phosphokinase value 2.5 Â upper limit normal and albumin !25 g/L), and use of effective contraceptive methods were eligible for this trial. Patients who received previous metformin, chemotherapy, concurrent experimental drugs, or who had symptomatic brain metastases, severe comorbidities (cardiac failure, previous myocardial infarction within the previous 4 months, cardiac arrhythmia, history of psychiatric disabilities), history of prior or concurrent malignancies at other sites, with the exception of surgically cured carcinoma in situ of the cervix and basal or squamous cell carcinoma of the skin and of other neoplasms without evidence of disease for at least 5 years, pregnancy or lactation, presence of any condition potentially hampering compliance with the study protocol and follow-up schedule were ineligible.
Treatment schedule
After signing the informed consent, patients were randomly allocated to receive the PEXG regimen with (arm A) or without (arm B) the addition of metformin. The PEXG regimen was administered every 4 weeks. Namely, cisplatin and epirubicin 30 mg/m 2 each on days 1 and 15, capecitabine 1,250 mg/m 2 on days 1 to 28, gemcitabine 800 mg/m 2 on days 1 and 15, steroids 8 mg every 2 weeks. Patients in arm A also received metformin 2 g/ day. Guidelines for dose-reduction and treatment delay have been previously reported (41) . Treatment was administered for 6 months with a maximum of 6 cycles or interrupted in the case of recurrence or progression, unacceptable toxicity, medical decision, or patient's refusal.
Study evaluation
Likewise our previous experience (41), assessment of antitumor treatment effects was made at baseline, every 8 weeks during chemotherapy and then every 3 months or in case of clinical suspicion of progressive disease. Complete blood, platelet, and differential counts were carried out every 2 weeks, whereas biochemistry profile was performed on a monthly basis.
Statistical design
The study was designed as a calibrated phase II clinical trial. Patients assigned to the standard arm formed the calibration group, in which the PFS-6 was expected to be 50%. Results obtained in the calibration arm were used to judge the results obtained in the experimental arm as follows: primary analysis was to be performed once at least 78 patients (39 per treatment group) were randomized and considered eligible for the per-protocol population. The PFS-6 is stated at a minimum desirable of 70%, whereas it is not acceptable at a level <50%. With 39 patients per arm we have a probability of erroneously concluding that the PFS-6 is >70% at 10% (two-sided a ¼ 0.1) and the probability of correctly concluding that this proportion is at least 50% at 90% (b ¼ 0.1). The study was monitored by an independent data safety monitoring committee (IDMC), which convened every 6 months. After 15, 30, and 60 patients had been enrolled, the IDMC compared toxicity data between treatment groups. After 60 patients had been enrolled, the IDMC conducted an interim analysis for efficacy. This study was registered with ClinicalTrials.gov, number NCT01167738.
Translational Relevance
In preclinical work and retrospective population studies, the antidiabetic drug metformin has been associated with antineoplastic activity and decreased burden of many cancers, including pancreatic cancer. There is therefore interest in the hypothesis that this drug might be repurposed for indications in oncology. We aimed to assess the efficacy of the addition of metformin to a standard systemic therapy in patients with metastatic pancreatic cancer, and we provide the first report of a clinical trial with a survival endpoint of metformin for an oncologic indication associated with the assessment of endocrine and metabolic phenotypic features and tumor molecular markers for sensitivity to metformin antineoplastic action.
Blood biochemistry
Fasting plasma glucose (FPG), serum creatinine, CA19.9, and bilirubin were measured in all patients at baseline (Advia 2400; Siemens Diagnostics) and FPG every month during treatment. At baseline, study participants were defined as having diabetes if they had at least one FPG ! 7.0 mmol/L or they were taking diabetes medications. Study participants with a FPG between 5.6 and 6.9 mmol/L were classified as having impaired fasting glucose (IFG). Study participants having FPG < 5.6 mmol/L were classified as having normal fasting glucose (NFG).
Hormonal and metabolic profile of treated patients
Circulating levels of ghrelin, gastric inhibitory polypeptide (GIP), glucagon-like peptide 1 (GLP-1), IL6, leptin, plasminogen-activator inhibitor type 1 (PAI-1), resistin, TNFa, visfatin, adiponectin, adipsin, glucagon and insulin before and during treatment (baseline, time 1 cycle 3 and 5) were measured by a multiplex bead-based assay with Luminex technology (Bio-Plex Pro Human Diabetes Assays; Bio-Rad Laboratories). Insulin resistance and b-cell function were estimated using the HOMA2 model (www.OCDEM.ox.ac.uk).
Genotyping of SNP rs11212617
Single-nucleotide polymorphism (SNP) rs11212617 at a locus containing the ataxia telangiectasia mutated gene can be used as predictive of clinical response because its minor allele (C) was associated with glycemic response to metformin in type 2 diabetes (42). The standard TaqMan-based allelic discrimination method (Applied Biosystems) was used for genotyping.
Tumor molecular markers for resistance of pancreatic cancer to metformin treatment
Tumor tissue obtained from the fine needle aspiration biopsy of the hepatic metastasis at the time of diagnosis was processed to extract RNA. Biopsy samples were disrupted with a homogenizer (Tissue Ruptor; Qiagen) and total RNA was extracted using mirVana Isolation Kit (Applied Biosystem) according to manufacturer's instructions. We obtained good-quality RNA from 21 samples. Reverse-transcription was performed using 5 mg total RNA with SuperScriptIII (Life Technologies). Real-time quantitative RT-PCR was performed to study the expression of selected genes with TaqMan Gene Expression Assays (TaqMan Array Gene Signature 96-Well Plate: IGFIR Signaling Plate, Insulin Signaling Plate, Pancreatic Adenocarcinoma Plate and PI3K Signaling Plate; Applied Biosystems). Results were analyzed with RT 2 Profiler PCR Array software (Qiagen).
Statistical analysis
Continuous variables are summarized as mean AE SD or median and interquartile range (IQR), according to their distribution. Survival and the time-to-event endpoints were estimated with the Kaplan-Meier method, and differences were analyzed using the logrank and Breslow test. Variables were compared with one-way unpaired or paired Student t-test, one-way ANOVA, Wilcoxon signed-rank test, Mann-Whitney U test, Kruskal-Wallis test, x 2 test, or Fisher exact test as appropriate. Data were log10-transformed when needed. Hazard ratios (HR) were estimated using Cox regression. Multivariate analyses were performed including in the models all variables significant at the level of P < 0.2 in the univariate analysis. We assessed the predictive value of changes in biomarker blood concentrations between baseline and before the start of cycle 3 and 5 with repeated measurement ANOVA, which assess the difference between the biomarker concentrations at the three time points, and the difference between the control and metformin group. We regarded P values of less than 0.05 as significant. All statistical analyses were performed using the SPSS 13.0 (SPSS Inc.).
Results

Study participants
Between August 2010 and January 2014, we screened 70 patients with metastatic pancreatic adenocarcinoma, and randomly assigned 60 patients to receive PEXG with (metformin group, n ¼ 31) or without metformin (control group, n ¼ 29; Fig. 1 ). At the preplanned interim analysis (60 enrolled patients), the IDMC ended the study for futility. Clinical characteristics at baseline are summarized in Table 1 . Eight patients (13%) were previously treated with surgery (four partial pancreasectomy and four explorative laparotomy). All patients at baseline had cytologic or histologic confirmed metastatic disease (liver 93%, lymph nodes 45%, peritoneum 22%, lung 15%, and bone 13%). When pancreatic disease was diagnosed, 38% of the patients had diabetes (with 25% patients with previously undiagnosed diabetes), 37% had IFG, and only 25% had NFG. Among these patients estimated b-cell dysfunction (HOMA2-%B) rather than insulin resistance (HOMA-%S) was the relevant determinant of diabetes (Supplementary Table S1 ). Baseline characteristics were balanced between the groups. 
Treatment administration
The study treatment in all patients was as first line. A total of 239 cycles were administered. Patients received a median of 4.5 (0.5-6) treatment cycles in the control group and 4 (0.5-6) cycles in the metformin group (P ¼ 0.26); the median duration of treatment was 4.9 months (3.1-6.4) and 4.7 months (1.7-6.1), respectively (P ¼ 0.31). Dose intensity of cisplatin (control vs. metformin; 83% and 85%), epirubicin ((81% and 83%), capecitabine (77% and 74%), and gemcitabine (74% and 77%) were similar between treatment groups. The median relative dose intensity of metformin (actual total dose/intended total dose) was 88%. In general, metformin was well tolerated and only two patients definitively withdrew treatment due to administration-correlated diarrhea and anorexia, respectively. Dose reductions occurred altogether in six patients and consisted in self-reduction of daily dose resulting in a dose-intensity of 60% (n ¼ 1); occasional omission of one to two pills (n ¼ 1); and temporary treatment interruption for 2 weeks during the whole treatment period (n ¼ 4).
Twenty-nine patients (48%) completed all the planned 6 months of treatment, 31 [14 in the control group and 17 in the metformin group (P ¼ 0.79)] interrupted the treatment due to radiological (n ¼ 23) or clinical (n ¼ 5) progression of disease, medical decision (n ¼ 1), consent withdrawal (n ¼ 1), or toxic death (n ¼ 1). After study treatment, 35 (58%) patients received second-line treatment: 21 in the control group and 14 in the metformin group (P ¼ 0.04).
Outcome
Fifteen patients of 29 [52%; 95% confidence interval (CI), 33-69] and 13 of 31 (42%; 95% CI, 24-59) were PFS-6 in the control group and the metformin group, respectively (P ¼ 0.61). Median PFS was 6.1 months (3.3-8.8) in the control group and 4.9 months (3.1-6.6) in the metformin group (log-rank P ¼ 0.22; Fig. 2A ). After adjustment for predictors of disease progression (Supplementary Table S2 ), the metformin hazard ratio for disease progression was 2 (1.05-3.8; P ¼ 0.036). The OS analysis was based on 59 (98%) deaths in 60 patients. Median OS was 10.4 months (9.1-11.7) in the control group and 6.8 months (4.1-9.5) in the metformin group (log-rank P ¼ 0.76; Fig. 2A ). After adjustment for predictors of OS resulted with P < 0.2 in univariate cox analysis (Supplementary Table S2 ), the metformin hazard ratio for death was 1.56 (0.87-2.8; P ¼ 0.13). OS and PFS were not different between control group and metformin group after stratification for baseline FPG, insulin, and insulin sensitivity baseline ( Supplementary Fig. S1 ). No complete response was observed. In the control group, 13 patients (45%) had PR and 10 patients (34.5%) had stable disease as best response (disease control rate: 79.5%); in the metformin group 11 patients (35.5%) had a partial response and 9 (29%) had stable disease (disease control rate: 64.5%; P ¼ 0.26; Fig. 2B ). Five patients (17%) and 9 patients (29%) progressed at first evaluation in the control and the metformin group, respectively (P ¼ 0.365). One patient in the control arm and two patients in the experimental arm were not assessed for response. Among patients with elevated CA19.9 basal value, a major biochemical response (43) was observed in 26% (7 of 27) of cases in control arm and in 38% (10 of 26) in experimental arm (P ¼ 0.38); a minor biochemical response was observed in 30% (8 of 27) and 27% (7 of 26), respectively (P ¼ 1). OS and PFS were not different between the two groups according to disease response (Fig. 2C ).
Metabolic and hormonal profile before and during treatment
As expected, a significant decrease was observed in FPG during treatment in the metformin group but not in the control group (Fig. 3A) . Baseline concentrations of ghrelin, GIP, GLP-1, IL6, leptin, PAI-1, resistin, TNFa, visfatin, adiponectin, adipsin, glucagons, and insulin were available for 52 of 60 patients. Mean baseline concentration of all analytes was similar in the control Repeated measures ANOVA comparing the change in the analyte concentrations between baseline and day 1 of cycle 3 and 5 was performed (Table 2) . Thirty-five of 60 patients received the cycle 5 and were eligible for the repeated measures ANOVA comparing the change in the analyte concentrations between baseline and day 1 of cycle 3 and cycle 5. Inadequate blood samples were drawn for some or all of the analytes in 9 of 35 patients (4 of 18 in control group and 5 of 17 in metformin group). Patients with no available data for any of the analytes were excluded from this part of the study. Even in these selected patients, OS [11.6 months (0.92-2.9) vs. 11.5 (4-19); P ¼ 0.72] and PFS [8.1 months (7.4-8.6) vs. 7 (4.1-9.9); P ¼ 0.39] were not different between control (n ¼ 14) and metformin group (n ¼ 12). In both groups, decreasing levels of visfatin, adiponectin, and adipsin were evident during the treatment. Leptin level increased in the control group but not in metformin group. However, a decrease in glucagon, GLP-1, resistin, and TNFa levels and an increase in insulin sensitivity and GIP levels were observed in the group treated with metformin but not in the control group.
SNP rs11212617 predicts glycemic response but not tumor response to metformin
The minor allele C of SNP rs11212617 at a locus containing the ataxia telangiectasia mutated gene was associated with metformin treatment success in type 2 diabetes. With the purpose to determine whether the same SNP can be used as a predictor of the clinical response in pancreatic cancer, 57 of 60 patients were genotyped. The A and C allelic frequencies of rs11212617 in our patients were 68% and 32%. The frequencies of three genotypes in all the patients were 11% (C/C), 54% (A/C), and 35% (A/A) and similar between the control and metformin group (Table 1 ). In the metformin group there was a significant relationship between SNP rs11212617 C allele and the metabolic response to metformin treatment with the highest FPG reduction after 1 month of treatment in patients with the CC genotype (CC: 2.19 AE 1.44 mmol/L, AC: 0.94 AE 1.46 mmol/L, AA: 0.87 AE 2.1 mmol/L; Fig.  3B ). As expected, in the control group no significant relationship between SNP rs11212617 C allele and FPG reduction was evident. OS and PFS were not different between the control and metformin group after stratification for rs11212617 genotypes (Fig. 3C ).
Molecular markers for response to metformin treatment
To determine whether the expression of genes related to insulin/IGFI signaling pathway, PI3K-AKT-mTOR signalling pathway and pancreatic adenocarcinoma specific pathway is associated with the response to metformin, the expression of 247 selected genes was evaluated on tumor tissue obtained from the fine needle aspiration biopsy of the hepatic metastasis in 22 out 60 patients at the time of diagnosis (7 patients in the control group, 15 patients in the metformin group). Because the primary endpoint of the trial was not met, a "true" population of responders was not identified. As a surrogate we divided the population into responders or not responders based on the median PFS (5.26 months; Fig. 4A ): control group, PFS 6.43 months (3.9-8.9) in responders (n ¼ 3) versus 1.87 months (0.59-3.14) in nonresponders (n ¼ 4; P ¼ 0.01); metformin group, PFS 7 months (6.5-7.5) in responders (n ¼ 9) versus 2.7 months (4.4-4) in nonresponders (n ¼ 6). Of the genes analyzed in the control group, 4 were differentially expressed among responders and nonresponders. ITPR1, MEF2C, NFATC3a, and PLCE1 were overexpressed in responder, whereas none was underexpressed. Of the genes analyzed in the metformin group, only one was differentially expressed among responders and nonresponders: MMP1 was underexpressed in responders. To test the association with the outcome, differentially expressed genes were tested in a univariate Cox regression. From this analysis, none of the genes was associated with OS and/or PFS (Fig. 4B) . Of note, basal expression of key genes involved in glucose metabolism and insulin/IGFI action (including insulin and IGFI receptors, glucose transporter 4, and glycogen synthase kinase-3b) were not predictive of the response to metformin treatment and more generally to chemotherapy treatment.
Discussion
The observation from retrospective studies that metformin might decrease the risk of cancer and mortality in patients with diabetes prompted the initiation of numerous preclinical and clinical studies to investigate metformin anticancer activity. Here we report the results of a randomized clinical trial assessing metformin as add-on to PEXG in patients with metastatic pancreatic cancer with PFS-6 as the primary endpoint. The sample size was originally defined based on the detection of a 40% increase in PFS-6 (from 50% to 70%), but the IDMC ended the study for futility at the preplanned interim analyses (60 patients). Even if our trial is underpowered to detect a small although clinically meaningful benefit from metformin treatment, the results suggest that the addition of a conventional antidiabetic dose of metformin to PEXG does not improve the patient outcome. This appears in agreement with the result just published by Sil Kordes and colleagues (44) , reporting that the addition of metformin to gemcitabine and erlotinib does not improve the clinical outcome of unselected and heterogeneous patients with advanced pancreatic cancer.
Strengths of our study include a randomized controlled design, the use of clinical endpoints rather than biomarker surrogates, the assessment of serum biomarkers of metformin action, the attempt to characterize tumor biomarkers and genetic susceptibility to metformin action. However, weaknesses include the unavailability of many tumor tissue samples (mainly due to difficulties in the procedure, low tumor yields, and relatively low patient compliance), the unavailability of plasma metformin concentrations during the treatment and an inadequate sample size to detect a small survival benefits or benefits confined to a small subset of patients with pancreatic cancer. As for the last point, we decided a priori to detect a large difference in outcome because many phase III trials testing new regimens in patients with advanced pancreatic cancer have not shown improvements in survival, despite promising results during phase II.
The PEXG regimen used in our study was the first to demonstrate in a phase III trial a statistically significant improvement in PFS and OS as compared with single-agent gemcitabine (41). Accordingly, this regimen is included among standard treatment options in Italian Association of Medical Oncology (AIOM) guidelines, together with FOLFIRINOX and nab-paclitaxel regimens. This trial was concluded (January 2014) before the gem-nab paclitaxel became available in Italy (March 2015). FOL-FIRINOX was shown to be superior to single-agent gemcitabine after trial start. However, we decided to not modify trial design because, albeit full-doses of PEXG regimen can be administered to a less selected population, it yields a similar outcome as compared with FOLFIRINOX (median OS of 10.4-10.6 months in the present series) and is more convenient from a patient perspective because has a more favourable toxicity profile, does not require prophylactic G-CSF support, a central venous catheter or portable infusion pumps, and halves monthly hospital accesses. Even if the results were negative, our study is important and raises several points for consideration. Metformin was well tolerated when combined with chemotherapy. No increase in the reported grade 3 or 4 toxic effects occurred and no nondiabetic patient treated with metformin had hypoglycemia or lactic acidosis. Nonetheless, considering the survival endpoints, a weak trend toward a worse outcome in metformin-treated patients was evident: 3.6 months less in OS, 1.2 months less in PFS with a statistically significant HR of 2.0 for disease progression in the multivariate Cox regression analysis, 10% less PFS-6, and 10% less RR. Even if not statistically significant, 0.8 months less of OS, 1.3 months less of PFS, and 7.2% less OS-6 were reported also by Sil Kordes (44) in metformin-treated compared with placebotreated patients. A lot of the chemotherapeutic drugs work through reactive oxygen species (ROS; ref. 45 ) and metformin could mitigate the effects of chemotherapy by modifying ROS generation (46) . These data should be interpreted with caution, given the limited number of patients and the presence of potential confounding biases and studies to better understand a potential antagonism between metformin and chemotherapy should be carried out in the future (47) .
One of the main mechanisms of the antineoplastic activity of metformin is thought to be the effect on host environment, such as the decrease in insulin concentration with reduction in the activity of the insulin receptor-PI3K-mTOR signaling pathway (12) . Taken together our data suggest that, despite the documented endocrine and metabolic changes induced by metformin treatment, these changes have no effect on cancer outcome. Moreover, baseline insulin levels, insulin and IGFI receptor expression on tumor tissue, and genetic susceptibility to metformin metabolic action did not correlate with the clinical outcome either in the metformin group or in the control group. We also evaluated whether patients who had a decrease in insulin concentrations between baseline and the day 1 of cycle 3 had a better OS or PFS versus those who did not have decreased insulin concentrations, as suggested by Sil Kordes and colleagues (44) , but no differences were evident (data not shown). Finally, studying gene expression on tumor tissue did not identify any gene related to insulin/IGFI signalling pathway and PI3K-AKT-mTOR signalling pathway associated with OS or PFS in the metformin group. In our study, adiponectin level resulted in an independent predictor both for death and disease progression. This is in agreement with recent in vivo studies (48) showing that, unlike most other cancers, adiponectin deficiency significantly alleviate pancreatic cancer growth and metastasis. This unconventional role of adiponectin in the promotion of pancreatic cancer progression could be explained by its potent antiapoptotic effects via the activation of AMPK/Sirt1/PGC1a signaling (48) .
In conclusion, studies using metformin for treating pancreatic cancer should not be abandoned, although caution is required in view of the potential antagonism with chemotherapy. Identifying prognostic or predictive factors of the response to metformin would be valuable for selecting patients most likely to benefit from metformin treatment. Critical aspects of such studies such as the concentrations of metformin achieved in neoplastic tissue, the presence of organic cation transporters on tumor cells, and the oxidative phosphorylation system (OXPHOS) of tumor should be investigated further in order to optimize patient selection and treatment outcomes. In particular the OXPHOS signatures of pancreatic cancer could be relevant in patient selection. In fact, some cancer cells use OXPHOS as major source of energy metabolism, and others are heavily dependent on glucose as a major energy source (49) . Because metformin have been known as inhibitors of mitochondrial OXPHOS (complex 1; 50), it could be used alone after maximum response to chemotherapy for "residual disease" in patients with OXPHOS-dependent cancer.
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